Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cerebral Cavernous Malformation in the Elderly

JAMA Neurol; ePub 2017 May 8; Flemming, et al

A recent prospective imaging study determined that the overall prevalence of older adults with cerebral cavernous malformation (CCM) is 0.46%. The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in patients with CCM. Researchers included 4,721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of total participants, 2,715 had an evaluable MRI. They found:

  • Of total participants who underwent MRI scans, 12 (0.44%) had CCM.
  • With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46%.
  • The age-adjusted prevalence was found to be 0.61% for the 50- to 59-year age group, 0.17% for the 60- to 69-year age group, 0.45% for the 70- to 79-year age group, and 0.58% for the 80- to 89-year age group.
  • The sex-adjusted prevalence was 0.41% for women and 0.51% for men.

Citation:

Flemming KD, Graff-Radford J, Aakre J, et al. Population-based prevalence of cerebral cavernous malformations in older adults. Mayo Clinic Study of Aging. [Published online ahead of print May 8, 2017]. JAMA Neurol. doi:10.1001/jamaneurol.2017.0439.

This Week's Must Reads

Fully Automated Test Gauges Processing Speed in MS, MS Mult Scler; ePub 2018 Aug 6; Patel, Shen, et al

Inflammation and Disability in Progressive-Onset MS, JAMA Neurology; ePub 2018 Aug 6; Hughes, et al

Mental Health’s Impact on Falls in Patients with MS, Mult Scler Relat Disord; ePub 2018 Jul 26; Kalron, et al

House-Call-Based Practice Viable for Advanced MS, Int J MS Care; ePub 2018 Aug 7; Healey, Zabad, et al

Detection of Chronic Active MS Lesions on 3T MRI, AJNR Am J Neuroradiol; 2018 Jul; Absinta, et al

Must Reads in Rare Diseases

FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16

Cerebral Cavernous Malformation in the Elderly , JAMA Neurol; ePub 2017 May 8; Flemming, et al

Behavioral Impairment Linked to Depression in ALS, Neurology; ePub 2016 Aug 5; Rabkin, Goetz, et al